Clinical bottom line
Ketamine and its derivative, esketamine, have emerged as promising treatments for individuals with treatment-resistant depression (TRD), offering rapid antidepressant effects that are distinct from traditional therapies. While both agents have shown efficacy in reducing depressive symptoms, esketamine, administered as a nasal spray, has received FDA approval for TRD, providing a novel therapeutic option. However, the use of these treatments requires careful consideration of potential side effects and long-term safety.
What the evidence shows
Ketamine, an NMDA receptor antagonist, has been studied for its rapid antidepressant effects in TRD. A landmark study by Zarate et al. (2006) demonstrated that a single intravenous infusion of ketamine resulted in significant improvement in depressive symptoms within hours, with effects lasting up to a week [PMID: 17074937]. This rapid onset contrasts with the delayed effects of conventional antidepressants.
Esketamine, the S-enantiomer of ketamine, has been developed as a nasal spray for TRD. The TRANSFORM-2 trial (2019) showed that esketamine, in combination with an oral antidepressant, led to a greater reduction in depressive symptoms compared to placebo plus an oral antidepressant [PMID: 30832968]. This study supported the FDA's decision to approve esketamine for TRD.
A meta-analysis by Bahji et al. (2021) further confirmed the efficacy of both ketamine and esketamine in reducing depressive symptoms, highlighting their potential as rapid-acting treatments for TRD [PMID: 33472596].
Caveats and uncertainty
Despite their efficacy, ketamine and esketamine are associated with several caveats and uncertainties. Both treatments can cause dissociative symptoms, increased blood pressure, and potential for misuse, necessitating careful monitoring and administration in controlled settings. The long-term safety and effects of repeated dosing remain areas of active investigation.
The rapid antidepressant effects of ketamine and esketamine may not be sustained without ongoing treatment, raising questions about maintenance strategies. Additionally, the high cost of esketamine and the need for administration in a healthcare setting may limit accessibility for some patients.
Further research is needed to elucidate the mechanisms underlying the antidepressant effects of ketamine and esketamine, as well as to identify biomarkers that predict response and guide personalized treatment approaches.
How this may change practice
The introduction of ketamine and esketamine offers a paradigm shift in the management of TRD, providing clinicians with rapid-acting therapeutic options for patients who have not responded to traditional antidepressants. These treatments may be particularly beneficial for patients with severe depression or those at immediate risk of suicide, where rapid symptom relief is critical.
As evidence continues to evolve, clinicians should remain informed about the latest research and guidelines to optimize the use of ketamine and esketamine in clinical practice. The development of standardized protocols for administration and monitoring, as well as strategies for long-term management, will be essential to maximize the benefits and minimize the risks associated with these treatments.